Subsequently, ceritinib demonstrated higher anti-tumor efficacy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib as well as in crizotinib naïve patients during ASCEND-2 [109] and ASCEND-3 [110] clinical trials. This evidence concerns the gene ALK and non-small cell lung carcinoma.